Loading...
ZyVersa Therapeutics, Inc.
ZVSA•NASDAQ
Healthcare
Biotechnology
$0.27
$0.03(12.50%)
ZyVersa Therapeutics, Inc. (ZVSA) Financial Performance & Income Statement Overview
Review ZyVersa Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-63258.83%
↓ 63258.83%
Net Income Growth
-9476.43%
↓ 9476.43%
Operating Cash Flow Growth
13.31%
↑ 13.31%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-111.93%
↓ 111.93%
ROIC
-23.95%
↓ 23.95%
ZyVersa Therapeutics, Inc. (ZVSA) Income Statement & Financial Overview
Review ZyVersa Therapeutics, Inc.'s (ZVSA) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $13039.00 | $0.00 | $2600.00 |
| Gross Profit | $0.00 | $13039.00 | $0.00 | -$2600.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $258.88M | $121245.00 | $436043.00 | $709049.00 |
| SG&A Expenses | $1.89B | $1.17M | $1.83M | $2.04M |
| Operating Expenses | $2.14B | $1.29M | $2.27M | $2.75M |
| Total Costs & Expenses | $0.00 | -$1.29M | $2.27M | $2.75M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $119.56M | $138062.00 | $131635.00 | $58.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $1733.00 | $2600.00 |
| EBITDA | -$2.14B | -$1.29M | -$2.27M | -$2.75M |
| EBITDA Ratio | ||||
| Operating Income | -$2.14B | -$1.29M | -$2.27M | -$2.75M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$112.36M | -$138062.00 | -$2.40B | -$58.00 |
| Income Before Tax | -$2.26B | -$1.42M | -$2.40B | -$2.75M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | -$2962.00 | $0.00 | $9707.00 |
| Net Income | -$2.26B | -$1.42M | -$2.40B | -$2.76M |
| Net Income Ratio | ||||
| EPS | -$0.73 | $0.72 | -$0.24 | -$3.31 |
| Diluted EPS | -$0.73 | $0.72 | -$0.24 | -$3.31 |
| Weighted Avg Shares Outstanding | $31.07M | $1.09M | $9.88M | $834915.00 |
| Weighted Avg Shares Outstanding (Diluted) | $31.07M | $1.09M | $9.88M | $834915.00 |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan